DRM02 (topical kinase inhibitor) for lesions of Rosacea

Written by on November 27, 2013 in clinical trials, New Rosacea Treatments with 0 Comments


A new topical, being called DRM02 has been listed at ClinicalTrials as being investigated as safe and effective for the lesions of rosacea.

ClinicalTrials is one way that rosacea sufferers find out about new potential treatments that are undergoing early clinical trials.

What is DRM02?

I know that each time I see a new trial listed with some new moniker I ask what is that? It is just some made up name, probably internal to Dermira, the compay developing the new potential treatment.

It gets worse also, just when you think you know all the latest names a company will change hands and rename everything.

It seems that DRM02 is the development name from Dermira, and is described as as a `Topical Kinase Inhibitor’.


DRM02 (formerly VAL-002) is a novel topical kinase inhibitor targeting inflammatory skin diseases.

DRM02 is a selective inhibitor of a novel kinase involved in signaling for differentiation and migration in key cell types.

Our objective with DRM02 is to achieve strong efficacy in inflammatory skin diseases, comparable to topical calcineurin inhibitors, without the risk of systemic toxicity.

DRM02 is currently in preclinical development in preparation for clinical trials.

There is little information online at the moment about this treatment. More information is likely to become public if the trials are successful.

Trial Details

Clinical Trial NCT01993446

A Safety and Efficacy Study of DRM02 in Subjects With Rosacea

The purpose of this study is to determine whether DRM02 is safe and effective in the treatment of rosacea when applied twice daily for 6 weeks.

This is a double-blind, randomized, vehicle controlled, study enrolling 30 subjects with rosacea and designed to assess the safety, tolerability, and preliminary efficacy of DRM02.

Safety will be assessed during the study, through adverse events, local skin responses, urinalysis, serum chemistry and hematology laboratory testing, physical examination and vital signs.

Preliminary efficacy will be assessed through inflammatory lesion counts, the Investigator’s Global Evaluation (IGE) and the Rosacea Signs and Symptoms (RSS) scale.

Primary Outcome Measures: Change in inflammatory lesion count

Estimated Enrollment: 30
Study Start Date: October 2013
Estimated Study Completion Date: March 2014
Estimated Primary Completion Date: February 2014

Related Articles

About the Author

About the Author: David Pascoe started the Rosacea Support Group in October 1998. .

Follow Rosacea Support

Subscribe via RSS Feed

Leave your comment here


Subscribe to Rosacea News

Enter your email address to receive the latest news about rosacea in your inbox.